HANSA BIOPHARMA AB |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 27.32 SEK | +0.44% |
|
-6.76% | +4.27% |
| Apr. 18 | Transcript : Hansa Biopharma AB, Q1 2024 Earnings Call, Apr 18, 2024 | |
| Apr. 18 | Hansa Biopharma AB Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
Valuation
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Capitalization 1 | 3,356 | 10,691 | 3,949 | 2,581 | 1,374 | 1,504 | - | - |
| Enterprise Value (EV) 1 | 2,765 | 9,319 | 3,096 | 1,876 | 1,509 | 1,978 | 2,237 | 2,726 |
| P/E ratio | -9.32 x | -24.1 x | -7.2 x | -3.63 x | -1.66 x | -2.37 x | -2.81 x | -3.58 x |
| Yield | - | - | - | - | - | - | - | - |
| Capitalization / Revenue | 987 x | 1,753 x | 116 x | 16.7 x | 10.2 x | 6.29 x | 4.39 x | 3.28 x |
| EV / Revenue | 813 x | 1,528 x | 91.3 x | 12.1 x | 11.3 x | 8.27 x | 6.53 x | 5.94 x |
| EV / EBITDA | -7.85 x | -22.2 x | -5.75 x | -3.25 x | -1.96 x | -3.69 x | -4.75 x | -11.4 x |
| EV / FCF | -8.18 x | -32.1 x | -6.4 x | -3.7 x | -2 x | -3.53 x | -6.13 x | -5.55 x |
| FCF Yield | -12.2% | -3.12% | -15.6% | -27.1% | -50.1% | -28.3% | -16.3% | -18% |
| Price to Book | 5.96 x | 8.16 x | 5.21 x | 4.26 x | -8.2 x | -3.49 x | -2.6 x | - |
| Nbr of stocks (in thousands) | 40,026 | 44,473 | 44,473 | 52,444 | 52,444 | 55,034 | - | - |
| Reference price 2 | 83.85 | 240.4 | 88.80 | 49.22 | 26.20 | 27.32 | 27.32 | 27.32 |
| Announcement Date | 2/6/20 | 2/4/21 | 2/3/22 | 2/2/23 | 2/2/24 | - | - | - |
1SEK in Million2SEK
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 3.4 | 6.098 | 33.9 | 154.5 | 134.1 | 239.2 | 342.6 | 458.7 |
| EBITDA 1 | -352.2 | -420.1 | -538.4 | -576.5 | -768.7 | -536 | -470.6 | -239 |
| EBIT 1 | -359.7 | -422.8 | -547 | -587 | -788.5 | -608.3 | -575.1 | -559 |
| Operating Margin | -10,579.41% | -6,933.54% | -1,613.57% | -379.9% | -588.02% | -254.3% | -167.84% | -121.87% |
| Earnings before Tax (EBT) 1 | -359.6 | -420.9 | -548.1 | -608.4 | -830.8 | -734.6 | -712.2 | -797.1 |
| Net income 1 | -360 | -420.9 | -548.3 | -609.6 | -831.7 | -734.9 | -712.5 | -797.5 |
| Net margin | -10,588.24% | -6,901.49% | -1,617.4% | -394.48% | -620.25% | -307.19% | -207.93% | -173.87% |
| EPS 2 | -9.000 | -9.980 | -12.33 | -13.57 | -15.83 | -11.52 | -9.715 | -7.633 |
| Free Cash Flow 1 | -338.2 | -290.6 | -483.6 | -507.5 | -755.9 | -560 | -365 | -491 |
| FCF margin | -9,947.15% | -4,764.97% | -1,426.66% | -328.43% | -563.74% | -234.09% | -106.52% | -107.05% |
| FCF Conversion (EBITDA) | - | - | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - | - | - |
| Dividend per Share 2 | - | - | - | - | - | - | - | - |
| Announcement Date | 2/6/20 | 2/4/21 | 2/3/22 | 2/2/23 | 2/2/24 | - | - | - |
1SEK in Million2SEK
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2021 S1 | 2021 Q4 | 2021 S2 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 | 2025 Q2 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 13.5 | 15.4 | 20.4 | 30.28 | 26.4 | 67.08 | 30.77 | 24.19 | 36.65 | 22.8 | 50.41 | 56 | 50.69 | 70.41 | 61.8 | 67.75 | 71.82 |
| EBITDA 1 | - | -162.1 | - | -134.6 | -167.4 | -139.1 | - | - | - | - | - | - | -153 | -108 | -127 | - | - |
| EBIT 1 | -236 | -162.8 | -311 | -135 | -167.8 | -139.5 | -144.7 | -182.3 | -228.5 | -202.2 | -175.5 | -159.4 | -161 | -141.7 | -149.7 | - | - |
| Operating Margin | -1,748.15% | -1,057.14% | -1,524.51% | -445.91% | -635.82% | -207.94% | -470.34% | -753.69% | -623.3% | -886.84% | -348.22% | -284.64% | -317.68% | -201.28% | -242.23% | - | - |
| Earnings before Tax (EBT) 1 | -236.5 | -163.2 | -311.6 | -138.4 | - | -153.5 | -146.6 | -205.1 | -251.1 | -250.4 | -124.2 | -218.6 | -175.6 | -169.9 | -170.5 | - | - |
| Net income 1 | -236.5 | -163.4 | -311.8 | -138.4 | -170.1 | -154 | -147.1 | - | -251.2 | -250.7 | -124.5 | -218.6 | -175.7 | -170 | -170.6 | - | - |
| Net margin | -1,752.01% | -1,061.04% | -1,528.43% | -457.19% | -644.31% | -229.49% | -478.15% | - | -685.32% | -1,099.56% | -246.89% | -390.36% | -346.6% | -241.45% | -276.03% | - | - |
| EPS 2 | -5.320 | -3.670 | -7.010 | -3.110 | -3.820 | -3.450 | -3.190 | -3.920 | -4.790 | -4.780 | -2.360 | -4.150 | -2.720 | -2.500 | -2.450 | -2.460 | -2.475 |
| Dividend per Share | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 7/15/21 | 2/3/22 | 2/3/22 | 4/21/22 | 7/19/22 | 10/20/22 | 2/2/23 | 4/20/23 | 7/20/23 | 10/26/23 | 2/2/24 | 4/18/24 | - | - | - | - | - |
1SEK in Million2SEK
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | 135 | 474 | 733 | 1,222 |
| Net Cash position 1 | 591 | 1,372 | 854 | 705 | - | - | - | - |
| Leverage (Debt/EBITDA) | - | - | - | - | -0.1752 x | -0.8843 x | -1.558 x | -5.113 x |
| Free Cash Flow 1 | -338 | -291 | -484 | -508 | -756 | -560 | -365 | -491 |
| ROE (net income / shareholders' equity) | -50.6% | -46.6% | -54.8% | -89.4% | -382% | -67% | -82% | -196% |
| ROA (Net income/ Total Assets) | - | - | - | - | - | - | - | - |
| Assets 1 | - | - | - | - | - | - | - | - |
| Book Value Per Share 2 | 14.10 | 29.40 | 17.00 | 11.60 | -3.200 | -7.830 | -10.50 | - |
| Cash Flow per Share | - | - | -10.80 | - | - | - | - | - |
| Capex 1 | 3.43 | 0.29 | 2.4 | 3.16 | 0.28 | 4 | 5 | 5 |
| Capex / Sales | 100.82% | 4.82% | 7.08% | 2.04% | 0.21% | 1.67% | 1.46% | 1.09% |
| Announcement Date | 2/6/20 | 2/4/21 | 2/3/22 | 2/2/23 | 2/2/24 | - | - | - |
1SEK in Million2SEK
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
C+
Sell
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
27.32
SEK
Average target price
105
SEK
Spread / Average Target
+284.33%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +4.27% | 137M | |
| +1.51% | 42.75B | |
| +8.57% | 41.34B | |
| +49.22% | 41.61B | |
| -12.36% | 26.59B | |
| +8.92% | 25.49B | |
| -25.13% | 18.12B | |
| +29.17% | 12.24B | |
| -3.12% | 11.76B | |
| +6.35% | 11B |
- Stock Market
- Equities
- HNSA Stock
- Financials Hansa Biopharma AB
